Neoplasms

All Conditions

Respiratory Tract (Lung and Bronchial) Diseases

Carcinoma

Carcinoma, Non-Small-Cell Lung

Lung Neoplasms

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

Carcinoma, Bronchogenic

Bronchial Neoplasms

All Drugs and Chemicals

Amino Acids

Tyrosine Kinase Inhibitors

Tyrosine

Peter Meldgaard, MD, PhD

Genetic rearrangements in the Anaplastic Lymphoma Kinase (ALK) gene result in the creation of a variety of oncogenic fusion proteins that drive malignancy in a subset of non-small cell lung cancers (NSCLC) patients. Treatment with the ALK small tyrosine kinase inhibitor (TKI) crizotinib has produced remarkable results for ALK-positive patients, however the current diagnostic tests used in the clinic are not sufficiently detailed and require a tumor biopsy.

The aim of this study is to use a new diagnostic test to detect ALK rearrangements using next generation sequencing, which will improve the diagnosis and treatment of ALK-positive NSCLC patients. Furthermore, this test will be performed on blood samples, making it minimally invasive for the patients. It is our believe that circulating tumor DNA (ctDNA) in blood can be employed as an easy accessible and comprehensive source of information to diagnose ALK-positive disease, but also as a means of monitoring patient response during treatment. Quantitation of the the amount of ALK rearrangement will give information about which patients benefit from treatment and when treatment is no longer effective. The project will be a multicenter study where blood samples will be collected every 6 weeks from patients treated at four major hospitals in Denmark.

This study will benefit future patients with lung cancer, as it will improve both the monitoring and evaluation of their treatment. Monitoring patients during treatment will provide more knowledge of disease progression and the effect of ALK-TKI treatment, contributing to a greater selection of patients, who will respond to treatment. This will potentially allow effective treatment to continue longer than with conventional methods

Blood-based Identification and Monitoring of Patients With ALK-translocated Lung Cancer

Identification of Response to ALK-targeted Treatment in Lung Cancer Patients by Monitoring Tumor DNA in Blood Samples

Aarhus University Hospital

Aalborg University Hospital

Odense University Hospital

University of Aarhus

Rare Diseases

Small Cell Lung Carcinoma

Small Cell Lung Cancer

Biopsy samples

Michèle BEAU-FALLER, MD

The majority of lung cancer patients have a tumor-derived genetic alteration in circulating plasma DNA that could be exploited as a diagnostic tool. The aim of this study is to evaluate if plasma DNA can be used as a valuable non invasive test to monitor disease progression without assessing the tumor.

Detection of Plasma DNA in Non Small Cell and Small Cell Lung Cancer Patients

Detection of Plasma DNA by Allelotyping in Non Small Cell and Small Cell Lung Cancer Patients. Evolution During Treatment and Follow-up.

University Hospital, Strasbourg, France

Emmanuel LAVOUE, Directeur Adjoint

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Bronchial Diseases

Antineoplastic Agents

Gefitinib

Chunming Ding, Ph.D

Ju Luan, Ph.D

Ju Luan, PhD

Wenfeng Li, MD

Wenfeng Li, Ph.D

A multi-centre observational, non-interventional study is to dynamically monitor the changes of circulating tumor DNA (ctDNA) in late stage NSCLC patients under Gefitinib treatment.

Dynamic Changes of Circulating Tumor DNA in Late Stage NSCLC Patients

A Multi-centre Observational Study on Dynamic Changes of Circulating Tumor DNA in Late Stage NSCLC Patients Under Gefitinib Treatment

Wenzhou Medical University

Professor

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Blood-based Identification and Monitoring of Patients With ALK-translocated Lung Cancer	NCT02718651	Carcinoma, Non-...		18 Years -	University of Aarhus
Detection of Plasma DNA in Non Small Cell and Small Cell Lung Cancer Patients	NCT00213798	Non-Small Cell ... Small Cell Lung...	Biopsy samples	18 Years -	University Hospital, Strasbourg, France
Dynamic Changes of Circulating Tumor DNA in Late Stage NSCLC Patients	NCT02804100	Carcinoma, Non-... Bronchial Neopl... Carcinoma, Bron... Lung Diseases Lung Neoplasms		18 Years -	Wenzhou Medical University

Spots Global Cancer Trial Database for plasma dna

Every month we try and update this database with for plasma dna cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for plasma dna

Every month we try and update this database with for plasma dna cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for plasma dna cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.